Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Section 4 of 6

Clinical evidence

225 evidence topics · 31 sources

Study summaries

OptimUM-02

Objective
Location and study date
Study status, dates, and number of sites in the ClinicalTrials.gov record
Study characteristicQuoted record
Overall status“Active, not recruiting”
Study start (actual)“2023-10-31”
Primary completion (estimated)“2027-01-15”
Study completion (estimated)“2028-01-15”
Sites“This study has 68 locations”
Last update posted“Last Update Posted 2026-02-17”
European Union dates in the EU trial record
FieldQuoted record
Start date in the European Union“2024-10-09”
Estimated recruitment start date“2024-07-01”
Estimated global end date“2027-12-31”
Study design
Multi-stage randomized open-label design in the ClinicalTrials.gov record

“This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).” (opens the source at this quote in a new tab)

“The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.” (opens the source at this quote in a new tab)

“The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.” (opens the source at this quote in a new tab)

“The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms to evaluate the primary endpoint of overall survival (OS).” (opens the source at this quote in a new tab)

Allocation, assignment model, and masking in the ClinicalTrials.gov record
Design characteristicQuoted record
Allocation“Randomized”
Interventional model“Sequential Assignment”
Masking“None (Open Label)”
Randomization ratios and stratification factors in the ASCO 2026 presentation
Study stageRandomization ratio shown in the study design figure
Phase 2a (darovasertib 300 mg BID plus crizotinib, darovasertib 200 mg BID plus crizotinib, investigator's choice)“2:2:1”
Phase 2b and phase 3 (darovasertib 300 mg BID plus crizotinib, investigator's choice)“2:1”
Crossover from the control arm

No evidence found.

Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11” (opens the source at this quote in a new tab)

“AEs from prior anti-cancer therapy that have not resolved to Grade ≤1” (opens the source at this quote in a new tab)

“Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids” (opens the source at this quote in a new tab)

“High risk of syncope or falls” (opens the source at this quote in a new tab)

“Active adrenal insufficiency, active colitis, or active inflammatory bowel disease” (opens the source at this quote in a new tab)

“History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids” (opens the source at this quote in a new tab)

“Active infection requiring systemic antibiotic therapy or active Hepatitis B/C” (opens the source at this quote in a new tab)

“Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug” (opens the source at this quote in a new tab)

“Females who are pregnant or breastfeeding” (opens the source at this quote in a new tab)

“History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies” (opens the source at this quote in a new tab)

“Contraindication for treatment with investigator's choice therapies as per applicable labelling” (opens the source at this quote in a new tab)

“History of stroke within the last 6 months of the first dose of study drug” (opens the source at this quote in a new tab)

“Impaired Cardiac function or clinically significant cardiac diseases, including angina pectoris or acute myocardial infarction <= 6 months prior to start of study treatment” (opens the source at this quote in a new tab)

Treatment
Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)
Investigator's choice treatment at baseline (stratification), n (%)Investigator's choice arm (N=103)
Ipilimumab + nivolumab“79 ( 76.7)”
Pembrolizumab or dacarbazine“24 ( 23.3)”
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
FDA guidance on progression-free survival as a regulatory endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 420 participants in the current ClinicalTrials.gov record
FieldQuoted record
Enrollment (estimated)“420”
Planned enrollment of 420 participants from record version 39, November 2024
Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024
Testing hierarchy and alpha allocation for secondary endpoints and overall survival

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, performance status, and LDH stratum (ASCO 2026 presentation)
CharacteristicDarovasertib plus crizotinib (N=210)Investigator's choice (N=103)
Age, mean (range), years“61.1 (22 - 85)”“61.5 (29 - 85)”
Female, n (%)“101 (48.1)”“52 (50.5)”
Race, White, n (%)“177 (84.3)”“83 (80.6)”
Race, non-White, n (%)“4 (1.9)”“4 (3.9)”
Race, not reported, n (%)“29 ( 13.8)”“16 ( 15.5)”
ECOG 0, n (%)“162 (77.1)”“87 (84.5)”
ECOG 1, n (%)“48 (22.9)”“16 (15.5)”
Stratification LDH at baseline (IRT), ≤ ULN, n (%)“120 (57.1)”“62 (60.2)”
Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%)“65 (31.0)”“29 (28.2)”
Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%)“25 (11.9)”“12 (11.7)”
Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)
CharacteristicDarovasertib plus crizotinib (N=210)Investigator's choice (N=103)
Time since first metastatic diagnosis, median (range), years“0.18 (0.0 – 8.1)”“0.19 (0.0 – 4.6)”
Size of largest metastatic lesion ≤ 3 cm, n (%)“119 ( 56.7)”“67 ( 65.0)”
Size of largest metastatic lesion 3.1 to 8.0 cm, n (%)“73 ( 34.8)”“31 ( 30.1)”
Size of largest metastatic lesion ≥ 8.1 cm, n (%)“18 ( 8.6)”“5 ( 4.9)”
Hepatic disease only, n (%)“127 ( 60.5)”“65 ( 63.1)”
Extrahepatic disease only, n (%)“11 ( 5.2)”“7 ( 6.8)”
Hepatic and extrahepatic disease, n (%)“72 ( 34.3)”“31 ( 30.1)”
Participants by age group and geographic region in the PFS subgroup figure (ASCO 2026 presentation)
SubgroupParticipants, darovasertib plus crizotinib and control
Age under 65 years“118, 64”
Age 65 years or older“92, 39”
Geographic region, USA“74, 36”
Geographic region, non-USA“136, 67”
Efficacy results
Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026
OutcomeBy blinded independent central reviewBy investigator assessment
Median PFS, darovasertib plus crizotinib, months (95% CI)“Darova + Criz: 6.9 (5.6, 8.3)”“Darova + Criz: 6.7 (5.6, 8.2)”
Median PFS, control, months (95% CI)“Control: 3.1 (1.8, 4.2)”“Control: 2.7 (1.7, 4.1)”
Hazard ratio (95% CI)“HR = 0.42 (0.30, 0.59)”“HR = 0.36 (0.26, 0.50)”
Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm
OutcomeBICR, darovasertib plus crizotinib (N=210)BICR, investigator's choice (N=103)Investigator, darovasertib plus crizotinib (N=210)Investigator, investigator's choice (N=103)
Complete or partial response, n (%)“78 (37.1)”“6 (5.8)”“83 (39.5)”“2 (1.9)”
Objective response rate, 95% CI“30.6, 44.1”“2.2, 12.3”“32.9, 46.5”“0.2, 6.8”
Objective response, odds ratio (95% CI)“10.8 (4.4, 26.4)”Reference“34.6 (8.1, 146.9)”Reference
Median duration of response, months (95% CI)“6.8 (5.5, 11.3)”“NE”“6.8 (4.8, 9.7)”“NE”
Complete response, partial response, or stable disease for at least 12 weeks, n (%)“154 (73.3)”“32 (31.1)”“156 (74.3)”“28 (27.2)”
Disease control rate, 95% CI“66.8, 79.2”“22.3, 40.9”“67.8, 80.1”“18.9, 36.8”
Disease control, odds ratio (95% CI)“7.7 (4.3, 13.5)”Reference“9.5 (5.3, 17.0)”Reference
Best overall response, n (%)BICR, darovasertib plus crizotinib (N=210)BICR, investigator's choice (N=103)Investigator, darovasertib plus crizotinib (N=210)Investigator, investigator's choice (N=103)
Complete response“5 (2.4)”“0”“0”“0”
Partial response“73 (34.8)”“6 (5.8)”“83 (39.5)”“2 (1.9)”
Stable disease“107 (51.0)”“43 (41.7)”“99 (47.1)”“39 (37.9)”
Progressive disease“13 (6.2)”“29 (28.2)”“15 (7.1)”“34 (33.0)”
Non-evaluable by RECIST“0”“1 (1.0)”“1 (0.5)”“4 (3.9)”
Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)
Subgroup (n, darovasertib plus crizotinib and control)ORR by BICR, darovasertib plus crizotinib (%)ORR by BICR, control (%)Median PFS by BICR, darovasertib plus crizotinib (months)Median PFS by BICR, control (months)
LDH normal (n=120, 62)“46.7”“8.1”“8.4”“4.2”
LDH above ULN and below 2x ULN (n=65, 29)“27.7”“3.4”“5.7”“1.8”
LDH 2x ULN or higher (n=25, 12)“16.0”“0”“3.1”“1.7”
Hepatic metastases (n=127, 65)“45.7”“3.1”“8.3”“2.9”
Extrahepatic metastases only (n=11, 7)“27.3”“0”“6.7”“8.3”
Hepatic and extrahepatic metastases (n=72, 31)“23.6”“12.9”“4.9”“2.8”
ECOG PS 0 (n=162, 87)“38.3”“5.8”“6.8”“3.1”
ECOG PS 1 (n=48, 16)“33.3”“6.3”“6.9”“3.1”
Largest lesion below 3 cm (n=119, 67)“42.9”“6.0”“8.3”“4.0”
Largest lesion 3 to 8 cm (n=73, 31)“34.3”“6.5”“5.6”“1.6”
Largest lesion 8 cm or larger (n=18, 5)“11.1”“0”“4.2”“1.7”
Control stratum ipilimumab plus nivolumab (n=158, 79)“37.3”“5.1”“6.9”“3.1”
Control stratum pembrolizumab or dacarbazine (n=52, 24)“36.5”“8.3”“5.8”“2.8”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)
OutcomeDarovasertib plus crizotinib (N=239)Investigator's choice (N=100)
Any TRAE, n (%)“235 (98.3)”“89 (89.0)”
Grade 3 or 4 TRAE, n (%)“97 (40.6)”“37 (37.0)”
Grade 5 TRAE, n (%)“1 (0.4)”“1 (1.0)”
Treatment-related serious adverse event, n (%)“22 (9.2)”“25 (25.0)”
TRAE leading to withdrawal, row not naming a drug, n (%)“2 (0.8)”“5 (5.0)”
TRAE leading to darovasertib withdrawal, n (%)“6 (2.5)”Not applicable
TRAE leading to crizotinib withdrawal, n (%)“24 (10.0)”Not applicable
TRAE leading to investigator's choice withdrawal, n (%)Not applicable“19 (19.0)”
TRAE leading to darovasertib dose reduction, n (%)“56 (23.4)”Not applicable
TRAE leading to crizotinib dose reduction, n (%)“63 (26.4)”Not applicable
Most common TRAE of any grade (20% or more), darovasertib plus crizotinib armDarovasertib plus crizotinib (N=239), n (%)
Any TRAE“235 ( 98.3)”
Diarrhea“203 ( 84.9)”
Nausea“179 ( 74.9)”
Peripheral edema“160 ( 66.9)”
Vomiting“119 ( 49.8)”
Dermatitis acneiform“100 ( 41.8)”
Fatigue“94 ( 39.3)”
Hypotension“79 ( 33.1)”
Hypoalbuminemia, dysgeusia, and dizziness, each“61 ( 25.5)”
Decreased appetite“57 ( 23.8)”
Most common TRAE of any grade (20% or more), investigator's choice armInvestigator's choice (N=100), n (%)
Any TRAE“88 ( 88.0)”
Diarrhea“29 ( 29.0)”
Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each“25 ( 25.0)”
Pruritus“24 ( 24.0)”
Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib armDarovasertib plus crizotinib (N=239), n (%)
Any grade 3 or 4 adverse event“97 ( 40.6)”
Diarrhea“24 ( 10.0)”
Syncope“17 ( 7.1)”
Hypotension“9 ( 3.8)”
Nausea and peripheral edema, each“7 ( 2.9)”
Anemia“6 ( 2.5)”
Grade 3 or 4 TRAE (2% or more), investigator's choice armInvestigator's choice (N=100), n (%)
Any grade 3 or 4 adverse event“37 ( 37.0)”
Alanine aminotransferase increased and aspartate aminotransferase increased, each“7 ( 7.0)”
Diarrhea“6 ( 6.0)”
Hepatitis“5 ( 5.0)”
Colitis“4 ( 4.0)”
Lipase increased, autoimmune hepatitis, and amylase increased, each“3 ( 3.0)”
Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each“2 ( 2.0)”
Study limitations
Summary

OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.

The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.

The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.

OptimUM-01

Objective
Location and study date
Registry study dates
Study characteristicQuoted record
Study start (actual)“2019-06-28”
Primary completion (estimated)“2027-01-29”
Study completion (estimated)“2027-06-15”
First-line cohort publication: enrolling centers
CountryQuoted institution
United States“Sarah Cannon Research Institute Nashville, TN”
United States“MD Anderson, Houston, TX”
United States“Thomas Jefferson University Hospital, Philadelphia, PA”
United States“Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA”
United States“Duke University Medical Center, Durham, NC”
United States“California Pacific Medical Center Research Institute, San Francisco, CA”
United States“University of Cincinnati Medical Center, Cincinnati, OH”
United States“Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI”
United States“Cleveland Clinic, Cleveland, OH”
United States“Sarah Cannon Research Institute at Healthone Denver, Denver, CO”
United States“Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA”
United States“Honor Health Research Institute, Scottsdale, AZ”
United States“Florida Cancer Specialist—North, FL”
United States“Florida Cancer Specialist—South, FL”
United States“St Joseph Mosaic Life Care, St Joseph, MO”
United States“Goshen Health Center for Cancer Care, Goshen, IN”
United States“Columbia University Medical Center, New York Presbyterian Hospital, New York, NY”
United States“The University of Texas MD Anderson Cancer Center, TX”
Australia“Westmead and Blacktown Hospitals, University of Sydney and Melanoma Institute Australia”
Australia“University of Queensland, Brisbane”
Canada“Princess Margaret Cancer Centre, Departments of Medicine and Immunology, University of Toronto, Toronto”
Study design
Registry design: nonrandomized, open-label, sequential assignment
Study characteristicQuoted record
Other study ID number“IDE196-001”
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Sequential Assignment”
Masking“None (Open Label)”
Eligibility criteria
Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants
Treatment
Study outcomes
Rationale for using RECIST v1.1 objective response rate as the primary endpoint
Registry primary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Registry: estimated enrollment
Study characteristicQuoted record
Enrollment (estimated), all cohorts of the basket study“336”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
First-line cohort: baseline characteristics of 44 participants
CharacteristicFirst-line cohort, N = 44
Age, median years (range)“64.5 (21, 80)”
Age less than 65 years, No. (%)“22 (50.0)”
Female, No. (%)“21 (47.7)”
Male, No. (%)“23 (52.3)”
Race White, No. (%)“41 (93.2%)”
Race Asian, No. (%)“1 (2.3%)”
Race other or not reported, No. (%)“2 (4.5%)”
ECOG PS 0, No. (%)“27 (61.4)”
ECOG PS 1, No. (%)“17 (38.6)”
Baseline LDH normal, No. (%)“29 (65.9)”
Baseline LDH above ULN, No. (%)“14 (31.8)”
Baseline LDH more than 2× ULN, No. (%)“7 (15.9)”
Largest metastatic lesion 3.0 cm or less, No. (%)“24 (54.5)”
Largest metastatic lesion 3.1 to 8.0 cm, No. (%)“15 (34.1)”
Largest metastatic lesion 8.1 cm or more, No. (%)“4 (9.1)”
Metastases hepatic only, No. (%)“23 (52.3)”
Metastases extrahepatic only, No. (%)“2 (4.5)”
Metastases hepatic and extrahepatic, No. (%)“18 (40.9)”
HLA-A∗02:01 negative, No. (%)“30 (68.2)”
HLA-A∗02:01 positive, No. (%)“12 (27.3)”
HLA-A∗02:01 unknown, No. (%)“2 (4.5)”
HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations
CharacteristicTreatment-naive, N = 13Overall, N = 101
Age, median years (range)“65.0 (21, 81)”“66.0 (21, 81)”
Female, n (%)“7 (53.8)”“44 (43.6)”
Race White, n (%)“13 (100.0)”“95 (94.1)”
ECOG PS 0, n (%)“6 (46.2)”“66 (65.3)”
ECOG PS 1, n (%)“7 (53.8)”“35 (34.7)”
Baseline LDH at or below ULN, n (%)“7 (53.8)”“36 (35.6)”
Baseline LDH above ULN and below 2× ULN, n (%)“4 (30.8)”“43 (42.6)”
Baseline LDH 2× ULN or higher, n (%)“2 (15.4)”“22 (21.8)”
Metastases hepatic only, n (%)“8 (61.5)”“51 (50.5)”
Metastases extrahepatic only, n (%)“2 (15.4)”“12 (11.9)”
Metastases hepatic and extrahepatic, n (%)“3 (23.1)”“38 (37.6)”
No prior lines of therapy, n (%)“13 (100)”“13 (12.9)”
Prior lines of therapyOverall, N = 101, n (%)
One prior line of therapy“20 (19.8)”
Two or more prior lines of therapy“67 (66.3)”
Not recorded, previously treated“1 (1.0)”
Efficacy results
First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control
OutcomeFirst-line cohort, N = 41
Objective response rate, No. (%)“14 (34.1)”
Objective response rate, 95% CI“20.1 to 50.6”
Best overall response CR, No. (%)“0 (0.0)”
Best overall response PR, No. (%)“14 (34.1)”
Best overall response SD, No. (%)“23 (56.1)”
Best overall response PD, No. (%)“4 (9.8)”
Duration of response, median months“9.0”
Duration of response, 95% CI“3.8 to 12.0”
Time to response, median months“2.0”
Disease control rate at 8 weeks, No. (%)“37 (90.2)”
Disease control rate at 8 weeks, 95% CI“76.9 to 97.3”
Disease control rate at 26 weeks, No. (%)“22 (53.7)”
Disease control rate at 26 weeks, 95% CI“37.4 to 69.3”
First-line cohort: confirmed response by HLA-A∗02:01 status
OutcomeHLA-A∗02:01 positive, n = 10HLA-A∗02:01 negative, n = 29
Objective response rate, No. (%)“3 (30.0)”“9 (31.0)”
Objective response rate, 95% CI“3.7 to 65.2”“15.3 to 50.8”
Best overall response PR, No. (%)“3 (30.0)”“9 (31.0)”
Best overall response SD, No. (%)“7 (70.0)”“16 (55.2)”
Best overall response PD, No. (%)“0 (0.0)”“4 (13.8)”
Disease control rate, No. (%)“10 (100.0)”“25 (86.2)”
Disease control rate, 95% CI“NA”“68.3 to 96.1”
Duration of response, median months“10.15”“9.03”
Duration of response, 95% CI“3.75 to NE”“1.94 to 9.03”
Time to response, median months“3.7”“1.9”
First-line cohort: response by baseline LDH
OutcomeLDH at or below ULN, n = 28LDH above ULN to 2× ULN, n = 7LDH above 2× ULN, n = 6
Objective response rate, No. (%)“8 (28.6)”“2 (28.6)”“4 (66.7)”
Objective response rate, 95% CI“13.2 to 48.7”“3.7 to 71.0”“22.3 to 95.7”
Best overall response SD, No. (%)“17 (60.7)”“4 (57.1)”“2 (33.3)”
Best overall response PD, No. (%)“3 (10.7)”“1 (14.3)”“0 (0.0)”
Disease control rate, No. (%)“25 (89.3)”“6 (85.7)”“6 (100)”
First-line cohort: response by tumor burden (largest metastatic lesion)
Outcome3 cm or less, n = 23Above 3 cm to 8 cm, n = 15Above 8 cm, n = 3
Objective response rate, No. (%)“9 (39.1)”“4 (26.7)”“1 (33.3)”
Objective response rate, 95% CI“19.7 to .61.5”“7.8 to 55.1”“0.8 to 90.6”
Best overall response SD, No. (%)“14 (60.9)”“7 (46.7)”“2 (66.7)”
Best overall response PD, No. (%)“0 (0.0)”“4 (26.7)”“0 (0.0)”
Disease control rate, No. (%)“23 (100.0)”“11 (73.3)”“3 (100.0)”
HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations
OutcomeTreatment-naive, N = 13Overall, N = 101
Objective response rate, n/N (%)“4/11 (36.4)”“19/86 (22.1)”
Objective response rate, 95% CI“10.9, 69.2”“13.9, 32.3”
Confirmed best overall response CR, n/N (%)“0/11 (0.0)”“0/86 ( 0.0)”
Confirmed best overall response SD, n/N (%)“6/11 (54.5)”“49/86 (57.0)”
Confirmed best overall response PD, n/N (%)“0/11 (0.0)”“9/86 (10.5)”
Confirmed best overall response not evaluable, n/N (%)“1/11 (9.1)”“9/86 (10.5)”
Disease control rate, n/N (%)“10/11 (90.9)”“69/86 (80.2)”
Median progression-free survival, 95% CI“3.6, 19.6”“3.7, 6.8”
Median overall survival, 95% CI“8.9, NE”“9.8, 26.3”
HLA-A∗02:01-positive expansion: second-line participants after tebentafusp
OutcomePrior tebentafusp (second line), N = 15
Objective response rate, n/N“(5/14)”
Objective response rate, 95% CI“12.8-64.9”
Disease control rate, %“85.7%”
Disease control rate, n/N“(12/14)”
Median duration of response“5.6 mos”
Median progression-free survival, 95% CI“3.65-NE”
Median overall survival, 95% CI“9.79-NE”
HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster
OutcomeHLA-A∗02:01 negative, treatment-naive, N = 29HLA-A∗02:01 negative, overall, N = 61
Objective response rate, n/N (%)“9/29 (31.0)”“16/61 (26.2)”
Objective response rate, 95% CI“15.3, 50.8”“15.8, 39.1”
Disease control rate, n/N (%)“25/29 (86.2)”“53/61 (86.9)”
Median progression-free survival, 95% CI“3.7, 9.2”“5.0, 7.8”
Median overall survival, 95% CI“12.0, 23.8”“11.7, 20.7”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
First-line cohort: treatment-emergent adverse event summary
Adverse eventAll grades, No. (%)Grade 3 or higher, No. (%)
Any AE“44 (100)”“23 (52.3)”
Serious AE“9 (20.5)”“8 (18.2)”
AE leading to discontinuation“3 (6.8)”“1 (2.3)”
AEs related to darovasertib leading to reduction“3 (6.8)”“0”
AEs related to crizotinib leading to reduction“4 (9.1)”“1 (2.3)”
Diarrhea“42 (95.5)”“1 (2.3)”
Nausea“37 (84.1)”“0”
Edema peripheral“27 (61.4)”“0”
Vomiting“23 (52.3)”“0”
Dermatitis acneiform“20 (45.5)”“0”
Hypoalbuminemia“19 (43.2)”“1 (2.3)”
Fatigue“18 (40.9)”“0”
Constipation“13 (29.5)”“1 (2.3)”
Dizziness“13 (29.5)”“1 (2.3)”
Decreased appetite“11 (25.0)”“0”
Alanine aminotransferase increased“9 (20.5)”“2 (4.5)”
Headache“9 (20.5)”“0”
Aspartate aminotransferase increased“8 (18.2)”“1 (2.3)”
Cough“8 (18.2)”“0”
Dyspnea“8 (18.2)”“0”
Hypophosphatemia“8 (18.2)”“0”
Hypotension“8 (18.2)”“1 (2.3)”
Anemia“7 (15.9)”“0”
Blood alkaline phosphatase increased“7 (15.9)”“0”
Dysgeusia“7 (15.9)”“0”
Blood creatinine increased“6 (13.6)”“0”
COVID-19“6 (13.6)”“0”
Generalized edema“6 (13.6)”“1 (2.3)”
Hypokalemia“6 (13.6)”“2 (4.5)”
Pruritus“6 (13.6)”“0”
Rash maculopapular“6 (13.6)”“0”
Vision blurred“6 (13.6)”“2 (4.5)”
Blood lactate dehydrogenase increased“5 (11.4)”“0”
Cancer fatigue“5 (11.4)”“0”
Face edema“5 (11.4)”“0”
Gastroesophageal reflux disease“5 (11.4)”“0”
Iron deficiency anemia“5 (11.4)”“3 (6.8)”
Periorbital edema“5 (11.4)”“0”
First-line cohort: treatment-related adverse event summary
Adverse eventAll grades, No. (%)Grade 3 or higher, No. (%)
Treatment-related AE“43 (97.7)”“12 (27.3)”
Treatment-related serious AE“4 (9.1)”“3 (6.8)”
Treatment-related AE leading to discontinuation“2 (4.5)”“1 (2.3)”
Diarrhea“40 (90.9)”“1 (2.3)”
Nausea“35 (79.5)”“0”
Edema peripheral“27 (61.4)”“0”
Vomiting“21 (47.7)”“0”
Dermatitis acneiform“19 (43.2)”“0”
Hypoalbuminemia“19 (43.2)”“1 (2.3)”
Fatigue“17 (38.6)”“0”
Dizziness“12 (27.3)”“1 (2.3)”
Decreased appetite“8 (18.2)”“0”
Hypotension“8 (18.2)”“1 (2.3)”
Constipation“7 (15.9)”“0”
Aspartate aminotransferase increased“6 (13.6)”“0”
Dysgeusia“6 (13.6)”“0”
Rash maculopapular“6 (13.6)”“0”
Alanine aminotransferase increased“5 (11.4)”“1 (2.3)”
Anemia“5 (11.4)”“0”
Blood alkaline phosphatase increased“5 (11.4)”“0”
Face edema“5 (11.4)”“0”
Generalized edema“5 (11.4)”“0”
Hypophosphatemia“5 (11.4)”“0”
Periorbital edema“5 (11.4)”“0”
Pruritus“5 (11.4)”“0”
First-line cohort: treatment-emergent serious adverse events
Serious adverse eventOverall population, N = 44, No. (%)
Any serious adverse event“9 (20.5)”
Ascites“1 (2.3)”
Bacteremia“1 (2.3)”
Cancer pain“1 (2.3)”
Cholecystitis“1 (2.3)”
Diarrhea“1 (2.3)”
Fall“1 (2.3)”
Generalized edema“1 (2.3)”
Pulmonary embolism (listed in two rows of the source table)“1 (2.3)”
Pancreatitis acute“1 (2.3)”
Sudden death“1 (2.3)”
First-line cohort: treatment-related serious adverse events
Serious adverse event related to study drugOverall population, N = 44, No. (%)
Any serious adverse event related to study drug“4 (9.1)”
Diarrhea“1 (2.3)”
Pulmonary embolism“1 (2.3)”
Syncope“1 (2.3)”
Sudden death“1 (2.%)”
HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events
Adverse eventOverall, N = 101, n (%)
Related adverse event“101 (100)”
Related serious adverse event“12 (11.9)”
Related grade 3 or higher adverse event“38 (37.6)”
Related adverse event leading to discontinuation“9 (8.9)”
Related adverse events leading to reduction“28 (27.7)”
Diarrhea“83 ( 82.2)”
Nausea“77 ( 76.2)”
Edema peripheral“71 ( 70.3)”
Vomiting“58 ( 57.4)”
Fatigue“55 ( 54.5)”
Dizziness“38 ( 37.6)”
Dermatitis acneiform“35 ( 34.7)”
Hypotension“33 ( 32.7)”
Study limitations
Summary

The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.

In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.

Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).

CLXS196X2101

Objective
Location and study date
Registry protocol number and study dates
Study characteristicQuoted record
Other study ID number“CLXS196X2101”
Study start (actual)“2016-02-01”
Primary completion (actual)“2022-01-07”
Study completion (actual)“2022-01-07”
Study design
Registry design and status: nonrandomized, open-label, single group; combination part terminated
Study characteristicQuoted record
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics by schedule and at the recommended dose for expansion
CharacteristicAll QD, n = 38All BID, n = 30300 mg BID (RDE), n = 18All patients, N = 68
Median age, years (range)“55 (26–76)”View highlighted excerpt for this quote“57 (33–78)”View highlighted excerpt for this quote“56.5 (38–76)”View highlighted excerpt for this quote“56 (26–78)”View highlighted excerpt for this quote
Male, n (%)“22 (57.9)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“36 (52.9)”View highlighted excerpt for this quote
Female, n (%)“16 (42.1)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“11 (61.1)”View highlighted excerpt for this quote“32 (47.1)”View highlighted excerpt for this quote
ECOG performance status 0, n (%)“37 (97.4)”View highlighted excerpt for this quote“25 (83.3)”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“62 (91.2)”View highlighted excerpt for this quote
ECOG performance status 1, n (%)“1 (2.6)”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“6 (8.8)”View highlighted excerpt for this quote
Lactate dehydrogenase above ULN, n (%)“23 (60.5)”View highlighted excerpt for this quote“15 (50.0)”View highlighted excerpt for this quote“8 (44.4)”View highlighted excerpt for this quote“38 (55.9)”View highlighted excerpt for this quote
No prior systemic therapy, n (%)“3 (7.9)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote“9 (13.2)”View highlighted excerpt for this quote
One prior systemic therapy, n (%)“19 (50.0)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“9 (50.0)”View highlighted excerpt for this quote“37 (54.4)”View highlighted excerpt for this quote
Two prior systemic therapies, n (%)“12 (31.6)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“14 (20.6)”View highlighted excerpt for this quote
More than two prior systemic therapies, n (%)“4 (10.5)”View highlighted excerpt for this quote“4 (13.3)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote
Any prior immunotherapeutic agent, n (%)“22 (57.9)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“36 (52.9)”View highlighted excerpt for this quote
Prior pembrolizumab, n (%)“11 (28.9)”View highlighted excerpt for this quote“10 (33.3)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“21 (30.9)”View highlighted excerpt for this quote
Liver-only metastases, n (%)“13 (34.2)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“9 (50.0)”View highlighted excerpt for this quote“27 (39.7)”View highlighted excerpt for this quote
Liver and other metastases, n (%)“20 (52.6)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“33 (48.5)”View highlighted excerpt for this quote
Maximum target lesion diameter, median mm (range)“39 (11–126)”View highlighted excerpt for this quote“35.5 (11–201)”View highlighted excerpt for this quote“40 (11–201)”View highlighted excerpt for this quote“36 (11–201)”View highlighted excerpt for this quote
Demographics, metastatic sites, and prior therapy

“The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No patients had received prior tebentafusp.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Efficacy results
Best overall response and progression-free survival by schedule and at the recommended dose for expansion
OutcomeAll QD, n = 38All BID, n = 30300 mg BID (RDE), n = 18All patients, N = 68
Complete response, n (%)“0”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Partial response, n (%)“2 (5.3)”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“5 (7.4)”View highlighted excerpt for this quote
Stable disease, n (%)“27 (71.1)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“12 (66.7)”View highlighted excerpt for this quote“45 (66.2)”View highlighted excerpt for this quote
Progressive disease, n (%)“9 (23.7)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote
Objective response rate, 95% CI“[0.6–17.7]”View highlighted excerpt for this quote“[3.8–30.7]”View highlighted excerpt for this quote“[1.4–34.7]”View highlighted excerpt for this quote“[3.3–18.2]”View highlighted excerpt for this quote
Disease control rate, n (%)“29 (76.3)”View highlighted excerpt for this quote“22 (73.3)”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“51 (75.0)”View highlighted excerpt for this quote
Disease control rate, 95% CI“[59.8–88.6]”View highlighted excerpt for this quote“[54.1–87.7]”View highlighted excerpt for this quote“[52.4–93.6]”View highlighted excerpt for this quote“[63–84.7]”View highlighted excerpt for this quote
Median progression-free survival, months (95% CI)“3.5 (3.5–5.4)”View highlighted excerpt for this quote“4.1 (3.5–7.2)”View highlighted excerpt for this quote“3.7 (2.1–5.4)”View highlighted excerpt for this quote“3.6 (3.5–5.4)”View highlighted excerpt for this quote
Progression-free survival rate at 4 months, % (95% CI)“36.8 (22.0–51.8)”View highlighted excerpt for this quote“50.0 (31.3–66.1)”View highlighted excerpt for this quote“44.4 (21.6–65.1)”View highlighted excerpt for this quote“42.6 (30.8–54.0)”View highlighted excerpt for this quote
Progression-free survival rate at 6 months, % (95% CI)“26.3 (13.7–40.8)”View highlighted excerpt for this quote“33.3 (17.5–50.0)”View highlighted excerpt for this quote“27.8 (10.1–48.9)”View highlighted excerpt for this quote“29.4 (19.1–29.2)”View highlighted excerpt for this quote
Progression-free survival rate at 12 months, % (95% CI)“0.0 (NE–NE)”View highlighted excerpt for this quote“26.7 (12.6–43.0)”View highlighted excerpt for this quote“22.2 (6.9–42.9)”View highlighted excerpt for this quote“11.8 (5.5–20.6)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion
Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion
Preferred termAll QD, n = 38, all gradesAll QD, grade 3 or higherAll BID, n = 30, all gradesAll BID, grade 3 or higher300 mg BID (RDE), n = 18, all grades300 mg BID (RDE), grade 3 or higherAll patients, N = 68, all gradesAll patients, grade 3 or higher
Participants with at least 1 adverse event, n (%)“35 (92.1)”View highlighted excerpt for this quote“11 (28.9)”View highlighted excerpt for this quote“28 (93.3)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“17 (94.4)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“63 (92.6)”View highlighted excerpt for this quote“17 (25.0)”View highlighted excerpt for this quote
Nausea, n (%)“26 (68.4)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“45 (66.2)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Diarrhoea, n (%)“15 (39.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“11 (61.1)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“31 (45.6)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Vomiting, n (%)“12 (31.6)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (30.9)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Alanine aminotransferase increased, n (%)“7 (18.4)”View highlighted excerpt for this quote“2 (5.3)”View highlighted excerpt for this quote“8 (26.7)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“5 (27.8)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote“4 (5.9)”View highlighted excerpt for this quote
Hypotension, n (%)“8 (21.1)”View highlighted excerpt for this quote“5 (13.2)”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote“6 (8.8)”View highlighted excerpt for this quote
Fatigue, n (%)“10 (26.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (13.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“14 (20.6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Asthenia, n (%)“6 (15.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“13 (19.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Aspartate aminotransferase increased, n (%)“5 (13.2)”View highlighted excerpt for this quote“2 (5.3)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“11 (16.2)”View highlighted excerpt for this quote“4 (5.9)”View highlighted excerpt for this quote
Dry skin, n (%)“2 (5.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Rash, n (%)“3 (7.9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Blood creatinine increased, n (%)“2 (5.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (10.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Constipation, n (%)“4 (10.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (10.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules

“The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary

CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.